Biogen Inc. (NASDAQ: BIIB) recently announced its acquisition of RayThera Inc. for a sum of up to $1 billion. This move aims to enhance Biogen's immunology pipeline and expand its presence in various disease areas. The agreement involves an initial payment to RayThera shareholders, with the majority of the total amount dependent on achieving future clinical and regulatory milestones. The acquisition is projected to be finalized in the third quarter of 2026. RayThera specializes in the exploration and creation of small-molecule treatments for immunological conditions, thereby contributing early-stage assets to Biogen's portfolio.